- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Puts New Limits on Oral MS Drug
Reacting to a death associated with the multiple sclerosis drug fingolimod (Gilenya), the FDA said patients with certain cardiac risk factors should not take the oral agent.
The death was reported last year and the agency had promised to investigate it.
In an announcement on Monday, the FDA said it still didn't know whether fingolimod caused the patient's death, but nevertheless it was adding new contraindications to the drug's label, as well as a beefed-up recommendation for monitoring patients after dosing.
Read the full story: http://hcp.lv/Md4ptW
Source: MedPage Today
Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS
November 21st 2023Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Read More
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 16th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Read More
FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis
October 23rd 2023The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Read More
